Navigation Links
Novartis's Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function
Date:7/29/2013

BURLINGTON, Mass., July 29, 2013 /PRNewswire/ --  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical trial data and thought leader opinion, Novartis's novel vasodilative therapy serelaxin has the potential to gain acceptance among cardiologists for the treatment of acute heart failure, given that it is predicted to reduce mortality and prevent worsening renal function. While cardiologists are most compelled by drugs that reduce patient mortality, the high price of novel acute heart failure treatments could offset cardiologist receptivity to such agents. Payers also indicate that they would only accommodate such high price premiums in the presence of substantial improvements in efficacy. Cardiorentis's ularitide is similarly predicted to reduce mortality as well as offer other improvements in efficacy and safety compared to current therapies.     

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled Acute Heart Failure: Can the Novel Vasodilators Serelaxin and Ularitide Fulfill the Unmet Needs Highlighted by Cardiologists? also finds that U.S. cardiologists regard reductions in acute heart failure hospital readmissions as an equally pressing unmet need to reducing patient mortality. However, none of the current or emerging therapies are expected to address the issue of patient rehospitalization. Although serelaxin was associated with a non-significant increase in rehospitalization in patient trials, this agent still received the highest preference share when compared to ularitide and Scios/Johnson & Johnson's Natrecor in Decision Resources' target product profile simulator.

The findings also reveal that all of the emerging acute heart failure therapies are set to surpass many of the current therapies in terms of both efficacy and safety. In particular, surveyed cardiologists express excitement for the novel vasodilative therapies, which are also expected to provide improvements in dyspnea over the current patient-share leader, furosemide (Sanofi's Lasix/Lasilix, generics).

"In the last 20 years, many of the therapies in development for acute heart failure resulted in disappointment," said Decision Resources Analyst Joseph Dwyer, M.Res, Ph.D. "The high attrition rate for drugs in the acute heart failure pipeline is largely accounted for by improper trial design stemming from poor understanding of the disease and the lack of identification of an ideal therapeutic window. The biologic vasodilator serelaxin is set to address some of the previous failures of acute heart failure therapies, and this new agent has the potential to fulfill the largest unmet needs in this patient population and could emerge as a truly breakthrough therapy."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
2. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
3. Cosmetic Surgery Solicitors Warn of Potential Risks Posed by Dermal Fillers
4. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
5. AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
6. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
7. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
8. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
9. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
11. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... --  HeartWare International, Inc . (NASDAQ: HTWR ) ... its financial results for the three and 12 months ... at 8:00 a.m. ET.  The company plans to release ... webcast.  On the conference call and webcast, management will ... quarter and business outlook.   --> ...
(Date:2/12/2016)... , Feb. 12, 2016  Sequent Medical, Inc. ... a study to evaluate the safety and effectiveness of ... treatment of ruptured intracranial aneurysms.  Prof Laurent Spelle ... in Paris, France and Principal ... France and Germany.  Although ...
(Date:2/12/2016)... 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ) ... will ring the Nasdaq Closing Bell at the Nasdaq ... at 4:00 p.m. ET on Tuesday, February 16, ... Adrian Adams , will perform the honorary bell ... p.m. ET.  A live webcast will be available at: ...
Breaking Medicine Technology:
(Date:2/14/2016)... (PRWEB) , ... February 14, 2016 , ... ... themselves without trained eating disorders professionals near their residence. The nature of the ... no transportation, child care or time allotted at work to make traditional appointments. ...
(Date:2/13/2016)... ... ... Cypress in Sun City is the place to be on March 3rd to learn about ... will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will ... offers. In addition, prizes will be given away and light refreshments will be served. ...
(Date:2/13/2016)... , ... February 13, 2016 , ... Many individuals looking ... protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved into ... once more, but without the high-carb repercussions. IsoPasta has 30 grams of protein ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... (INS) states that vein visualization technology should be used to ensure patient safety ... the world, the INS Standards mandate the use of vein visualization technology in ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage ... to perfection, go out of their way to be romantic, and may exaggerate a ... look at any online dating profile. , A recent study from Queendom.com ...
Breaking Medicine News(10 mins):